Swiss National Bank Has $3.49 Million Stock Position in Bausch Health Cos Inc. $BHC

Swiss National Bank trimmed its position in Bausch Health Cos Inc. (NYSE:BHC) by 1.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 537,660 shares of the company’s stock after selling 6,200 shares during the quarter. Swiss National Bank owned approximately 0.15% of Bausch Health Cos worth $3,488,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BHC. Maple Rock Capital Partners Inc. increased its position in Bausch Health Cos by 156.7% in the fourth quarter. Maple Rock Capital Partners Inc. now owns 5,300,000 shares of the company’s stock worth $42,718,000 after purchasing an additional 3,235,100 shares during the period. Compass Rose Asset Management LP grew its position in shares of Bausch Health Cos by 366.7% during the 4th quarter. Compass Rose Asset Management LP now owns 2,100,000 shares of the company’s stock worth $16,926,000 after buying an additional 1,650,000 shares during the period. Renaissance Technologies LLC grew its position in shares of Bausch Health Cos by 1,761.5% during the 4th quarter. Renaissance Technologies LLC now owns 495,172 shares of the company’s stock worth $3,991,000 after buying an additional 468,572 shares during the period. Vestal Point Capital LP acquired a new position in shares of Bausch Health Cos during the 4th quarter worth about $2,015,000. Finally, D. E. Shaw & Co. Inc. grew its position in shares of Bausch Health Cos by 84.1% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 544,707 shares of the company’s stock worth $4,392,000 after buying an additional 248,871 shares during the period. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Bausch Health Cos

In other Bausch Health Cos news, Director John Paulson acquired 34,721,118 shares of the business’s stock in a transaction dated Thursday, August 14th. The shares were acquired at an average price of $9.00 per share, for a total transaction of $312,490,062.00. Following the acquisition, the director directly owned 70,755,869 shares of the company’s stock, valued at approximately $636,802,821. This trade represents a 96.35% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders bought 44,316,834 shares of company stock worth $369,628,560. Insiders own 8.05% of the company’s stock.

Bausch Health Cos Trading Down 2.5%

NYSE:BHC opened at $7.5950 on Thursday. Bausch Health Cos Inc. has a fifty-two week low of $4.25 and a fifty-two week high of $9.85. The company has a debt-to-equity ratio of 141.90, a current ratio of 1.31 and a quick ratio of 0.98. The stock has a market capitalization of $2.81 billion, a PE ratio of 29.21 and a beta of 0.41. The business’s 50-day simple moving average is $6.54 and its 200-day simple moving average is $6.04.

Bausch Health Cos (NYSE:BHC) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.97 by ($0.07). Bausch Health Cos had a net margin of 0.99% and a negative return on equity of 852.36%. The business had revenue of $2.57 billion for the quarter, compared to the consensus estimate of $2.47 billion. Bausch Health Cos has set its FY 2025 guidance at EPS. Sell-side analysts expect that Bausch Health Cos Inc. will post 4.41 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Royal Bank Of Canada boosted their target price on Bausch Health Cos from $8.50 to $10.00 and gave the stock a “sector perform” rating in a research report on Friday, May 2nd. Wall Street Zen upgraded Bausch Health Cos from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Three investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $9.00.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.